Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Novavax maintains a Hold rating as it transitions to a royalty-driven model, with shrinking direct product sales and a focus on partner revenue. NVAX's COVID-19/flu vaccine partnership with Sanofi is ...

(Reuters) -Novavax on Thursday provided preliminary adjusted revenue for 2026 and pushed back its profitability target by a year to 2028 as the biotech awaits key product launches from its partnership ...

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 12.3% in the afternoon session after the company reported better-than-expected first-quarter 2026 results.

Why Novavax Stock Is Back on Investor Radars Novavax (NVAX) has been catching investor attention again after recent trading swings, with the stock closing at US$9.06 and showing mixed short term ...

Novavax on Wednesday beat Wall Street estimates for first-quarter revenue, as upfront and milestone payments from vaccine supply and licensing deals helped offset pressure ​from sagging demand, ...

Novavax earned approval for its COVID-19 vaccine, Nuvaxovid, in various countries. In the U.S., it is still under Emergency Use Authorization. However, the biotech is now seeking full approval.

Vaccine biotechnology company Novavax (NASDAQ:NVAX) will be reporting results this Wednesday before market open. Here’s what you need to know. Novavax beat analysts’ revenue expectations last quarter, ...

Add Yahoo as a preferred source to see more of our stories on Google. Novavax, sold under the brand name Nuvaxovid, is a protein-based COVID-19 vaccine — the same technology used to develop many other ...

Shares of Moderna (NASDAQ:MRNA) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday’s close of $54.35. The intraday move extends what has already been a powerful 2026 ...

Novavax's protein-based shot is an option for COVID vaccination this season, joining refreshed formulas from Moderna and Pfizer. Jessica was a writer on the Wellness team, with a focus on health ...